info@seagull-health.com
SeagullHealth
语言:
search
new
What is the therapeutic effect of Elacestrant?
500
Article source: Seagull Pharmacy
Jun 19, 2025

Elacestrant was developed and produced by Stemline, the United States, and was approved by the U.S. Food and Drug Administration (FDA) in January 2023, becoming the only oral selective estrogen receptor degrader(SERD) drug on the market. Elacestrant is not currently available in China. You can follow the National Food and Drug Administration or the relevant official website to learn about the drug information.

What is the therapeutic effect of Elacestrant?

Elacestrant is an innovative selective estrogen receptor degrader(SERD) that performs well in the treatment of advanced or metastatic breast diseases. It is especially suitable for postmenopausal female or adult male patients who are positive for estrogen receptor (ER), negative for human epidermal growth factor receptor 2 (HER2), and carry mutations in the estrogen receptor alpha gene (ESR1). By directly binding to estrogen receptors, Elacestrant induced its degradation, thereby effectively blocking estrogen signaling pathways, significantly prolonging the patient's progression-free survival (PFS) and improving overall survival (OS).

Elacestrant medication guidance?

In order to fully utilize the therapeutic effect of Elacestrant, patients must follow correct medication guidance.

Recommended dosage

The recommended dose of Elacestrant is 345 mg once a day, taken orally with food. Make sure to take the medication at the same time every day and swallow the whole tablet without chewing, crushing or splitting the tablets.

Things to note

If you miss taking the medication for more than 6 hours or vomiting occurs, please skip this medication and take the next dose at the scheduled time the next day. During the use of Elacestrant, patients may experience side effects such as fatigue, nausea, diarrhea and joint pain, but these symptoms are usually mild and tolerated.

Regular monitoring

Before and during the initiation of Elacestrant, patients should regularly monitor indicators such as blood lipids, liver function, and blood cell count, and promptly detect and deal with potential adverse reactions.

Correct medication guidance is crucial to the therapeutic effect of Elacestrant. Patients should follow the recommended dose and medication time, pay attention to potential side effects, and regularly monitor relevant indicators.

Elacestrant storage method?

In addition to clarifying the therapeutic effect of Elacestrant and understanding the medication guidance of Elacestrant, correct storage methods are also crucial to maintaining the efficacy of Elacestrant.

Storage temperature

Elacestrant should be stored in an environment of 20°C to 25°C (68°F to 77°F). The permissible temperature range is 15°C to 30°C (59°F to 86°F).

Avoid exposure

Ensure that Elacestrant is not exposed to high humidity and direct sunlight to prevent the drug from absorbing moisture, spoiling or breaking down the active ingredients.

Keep Elacestrant out of reach of children and keep the medication properly to avoid loss or misuse.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Elacestrant(Orserdu)
Elacestrant(Orserdu)
Advanced or metastatic breast cancer that is ER-positive, HER2-negative, and...
WeChat Scan
Free Inquiry
Recommended Articles
How effective is Elacestrant?
In the treatment of breast diseases, the emergence of Elacestrant is of great significance. As an oral SERD, it is able to directly degrade estrogen receptors, thereby inhibiting the growth of disease...
Is Elacestrant(ORSERDU) effective?
The launch of the breast disease treatment drug ORSERDU/Elacestrant has brought new vitality to countless patients. This drug selectively degrades estrogen receptors and effectively blocks the growth ...
Guidelines for the use of Elacestrant
Elacestrant(Orserdu) is a novel estrogen receptor antagonist for patients with specific types of breast cancer. This article will systematically explain the key information of the drug from three aspe...
How to use Elacestrant?
Elacestrant is a novel estrogen receptor antagonist suitable for patients with specific types of advanced breast cancer. Correct use of this drug can not only improve the efficacy, but also reduce the...
Side effects of Elacestrant
Elacestrant is a novel estrogen receptor antagonist that provides an important therapeutic option for specific breast cancer patients. However, similar to other drugs, a series of side effects may occ...
Side effects caused by Elacestrant
Elacestrant, the main component of Elacestrant, is mainly adapted to postmenopausal women or adult men with breast-related diseases. As a novel selective estrogen receptor degrader, it has shown signi...
Tazemetostat's indications
Tazemetostat is a selective oral EZH2 (Enhancer of Zeste Homolog 2) inhibitor. EZH2 is an enzyme responsible for histone methylation in cells and has an important impact on cell proliferation and...
Tazemetostat(TAZVERIK) provides a new treatment path for patients with multiple refractory and recurrent diseases
Tazemetostat(TAZVERIK) is a novel EZH2 inhibitor that provides a new treatment pathway for patients with multiple refractory and recurrent diseases. It blocks the growth and spread of lesion cell...
Related Articles
What are the Precautions for Taking Elacestrant (Orserdu)?
Elacestrant (Orserdu) is the first oral selective estrogen receptor degrader (SERD). It was approved by the FDA in 2023 for the treatment of advanced or metastatic breast cancer that is estrogen recep...
Side Effects of Elacestrant (Orserdu)
Elacestrant (Orserdu) is an estrogen receptor antagonist, primarily indicated for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutat...
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is an estrogen receptor antagonist, primarily indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastati...
What Are the Indications of Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel estrogen receptor antagonist. It was approved for marketing by the U.S. FDA in 2023, providing a precise treatment option for patients with advanced breast cancer harb...
What Are the Purchase Channels for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel estrogen receptor antagonist that plays an important role in the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.What Are th...
Side effects caused by Elacestrant
Elacestrant, the main component of Elacestrant, is mainly adapted to postmenopausal women or adult men with breast-related diseases. As a novel selective estrogen receptor degrader, it has shown signi...
Side effects of Elacestrant
Elacestrant is a novel estrogen receptor antagonist that provides an important therapeutic option for specific breast cancer patients. However, similar to other drugs, a series of side effects may occ...
What is the therapeutic effect of Elacestrant?
Elacestrant was developed and produced by Stemline, the United States, and was approved by the U.S. Food and Drug Administration (FDA) in January 2023, becoming the only oral selective estrogen recept...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved